CD276 and cancer: With antitumor activity against solid tumor shown by B7‐H3‐specific monoclonal antibodies (mAbs),29 antibody‐drug conjugates30 and B7‐H3‐targeting CAR‐T cells,31 B7‐H3 becomes a promising target for cancer immunotherapy and serves as a potential immunotherapy target for SCCE.